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OBJECTIVES: To evaluate usage and persistency of atypical
anti-psychotics among schizophrenia patients utilizing a
managed care database. METHODS: A retrospective study
utilizing the Pharmetrics claims database was conducted. All
patients with a diagnosis of schizophrenia (ICD 9 codes 295.0 to
295.9) in 2003 were included in the analysis. Patients were
required to have a minimum 12 months of continuous eligibility
following their index diagnosis. A subset of patients was classi-
ﬁed on the basis of ﬁrst atypical anti-psychotic mono-therapy
treatment (Risperidone, Olanzapine, Quetiapine, Aripiprazole or
Ziprasdone). Persistency (%) in this group was calculated by
following a closed cohort of patients on a speciﬁc atypical anti-
psychotic therapy from month one to month 12. Patients who
dropped-off therapy and then re-initiated the same atypical agent
within the 12 month period (re-starts) were included in the
analysis. RESULTS: A total of 6418 patients were analyzed. Of
these 60.4% were currently on an antipsychotic (typical/ atypi-
cal) treatment. Atypical mono-therapy including clozapine was
used by 51.7%, combination atypical therapy by 30.5%; the
remaining 17.8% of the currently treated cohort were on typical
anti-psychotics. The subset of 1777 patients on atypical mono-
therapy consisted of 668 (37.6%) Risperidone; 754 (42.4%)
Olanzapine; 228 (12.8%) Quetiapine; 105 (5.9%) Ziprasidone.
Aripiprazole patients (n = 24) were excluded from this analysis.
Olanzapine and Risperidone patients were more persistent (60%
and 59%) compared to Quetiapine (44%) and Ziprasidone
(40%). CONCLUSION: Majority of schizophrenia patients are
currently treated with atypical anti-psychotics with Olanzapine
and Risperidone in the lead in terms of treatment share and
persistency.
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OBJECTIVES: The purpose of this study was to quantify the
extent of nonadherence across antidepressants and to determine
the rate of switching within the class. METHODS: Blinded pre-
scription data from two national retail pharmacy chains was
analyzed for 417,002 patients taking sertraline, venlafaxine, par-
oxetine, and escitalopram. Cumulative drug consumption (total
days supply) during the one year follow up period was employed
as the measure of adherence. Kaplan Meier estimates of survival
(persistence) curves were used to assess the time to discontinua-
tion and to calculate the one year rate of discontinuation. Base-
line patient characteristics, including age, gender, geographic
region, median income, index quantity dispensed, population
density, co-pay, and index reﬁll and days supply prescribed were
analyzed. RESULTS: Adherence data across these antidepres-
sants showed that escitalopram patients obtained the fewest days
of medication (161.26), and venlafaxine patients had the greatest
number of days of therapy (191.54). At day 60, 30% of ven-
lafaxine patients, 34% of sertraline patients, and 40% of parox-
etine and escitalopram patients discontinued therapy. After 6
months, 60% of venlafaxine patients, 64% of sertraline patients,
68% of paroxetine patients, and 70% of escitalopram patients
discontinued therapy. The rate of switching to another agent was
3.67% for paroxetine, 3.14% for venlafaxine, 2.95% for escit-
alopram, and 2.1% for sertraline. CONCLUSION: Even though
antidepressant medications are effective in controlling depres-
sion, their effectiveness is reduced by the lack of adherence to
therapy. Adherence can vary signiﬁcantly across the agents
within a class. Efforts to maintain patients on antidepressant
therapy at the initiation of treatment are needed and most likely
will affect future adherence.
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OBJECTIVES: This study assesses the validity and responsive-
ness over changes of the English version of the S-QoL, ﬁrst
schizophrenia-speciﬁc health-related quality of life scale devel-
oped from patients’ viewpoint on the need-based framework.
METHODS: The S-QoL, comprising 41 items exploring eight
dimensions (Psychological Well-being, Self-esteem, Relations
with Family, Relations with Friends, Resilience, Physical Well-
being, Autonomy and Sentimental Life), was ﬁrst developed and
validated in French. After a standard backward-forward trans-
lation process, its English version was tested in a sample of
patients with schizophrenia. Two assessments were performed:
baseline and 12 weeks later. Psychometric properties (validity
and sensitivity over changes) were evaluated using methods from
Classical Test Theory, Rasch analyses and structural equation
modelling. RESULTS: A total of 128 patients ﬁlled-in the S-QoL.
The factorial structure of the original version was globally
retrieved. The questionnaire was well accepted (missing dimen-
sion rates lower than 3%). Cronbach’s alphas were greater than
0.70 for 6 of the 8 dimensions. The S-QoL dimensions and total
score were statistically correlated with depression assessed with
the Calgary Depression Scale for Schizophrenia (CDSS), and
severity of symptoms measured by the Positive and Negative
Symptoms Scale (PANSS). Using the sub-sample of patients rated
“Very much Improved” or “Improved” on the Clinical Global
Impression of Improvement (CGI-I) at Week 12, all the dimen-
sions and the total score were statistically signiﬁcantly improved.
Five of the dimensions, as well as the total score, reached an
effect size of at least 0.50 indicating an at least moderate change
on health status. CONCLUSION: These results strengthen the
usefulness of assessing the impact of schizophrenia on patients’
everyday life with the S-QoL, speciﬁcally designed for assessing
the health-related quality of life of patients with schizophrenia.
Its sensitivity to changes in health state is of major interest for
evaluative purposes.
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OBJECTIVES: The objectives were to develop and validate
a sleep-speciﬁc patient-reported outcomes instrument in
US-English and US-Spanish that can be used in clinical trials.
METHODS: In the development phase, interviews were
conducted with 25 US-English speaking participants suffering
from insomnia. Participants’ comments were reviewed by two
US-Spanish speakers to ensure commonality. Item generation was
conducted simultaneously in the two languages to ensure con-
ceptual equivalence. The face and content validity of the newly
developed instrument (Sleep Impact Scale [SIS]) was tested in 10
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US-English speaking and 16 US-Spanish speaking participants
with primary or secondary insomnia. Data for the validation of
the SIS were collected alongside a North American 4-week multi-
center, double-blind, placebo-controlled, randomized, parallel-
group study in primary and secondary insomnia patients. Item
level analyses including assessment of missing data, item-item
correlations, Principal Components Analysis, and clinical valid-
ity were conducted. Items with ﬂoor or ceiling effects were can-
didates for deletion, as were items which did not load with any
particular domain. Once domains were determined, validity of
the domains was assessed through internal consistency reliability,
item-domain concurrent and divergent validity, clinical validity,
concurrent validity and conﬁrmatory factor analysis. Addition-
ally, responsiveness and minimal important difference estimates
were determined. RESULTS: Patient interviews resulted in
55 items in 8 domains. During item reduction and validation,
18 items were deleted based on their content validity, high
ceiling effect (>40%), redundancy (Inter-item Pearson correla-
tion > 00.80) no or multifactor loading and/or failure to meet the
Item-level discriminant validity criterion. After reduction, the
ﬁnal SIS consists of 35 items in 7 domains. CONCLUSION:
The SIS was developed to account for US-English and US-Spanish
cultural differences. The validation study provides evidence on
the psychometric properties of the SIS. The SIS has been shown
to adequately meet the criteria for a validated measure to be used
in clinical trials.
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OBJECTIVES: To comprehensively explore existing quality of
life (QoL) measures in alcoholism (alcohol abuse and alcohol
dependence). METHODS: Systematic searches of Scopus (1990–
2007) were conducted using terms synonymous with alcoholism
combined with terms associated with measuring QoL. RESULTS:
In total, 618 abstracts were identiﬁed detailing the use of 16
generic patient-reported measures to assess QoL in alcoholism.
Upon further examination (ie searching Scopus using the QoL
measure as a search term from date of development) nine mea-
sured health status and seven assessed generic QoL, with varying
deﬁnitional criteria and domain focus. The SF-36 and EQ-5D, in
particular, have been used widely but frequently misinterpreted
as measures of QoL rather than health status. One alcohol-
speciﬁc QoL measure was identiﬁed; the AlQoL 9, a scale that
the authors have claimed to epitomise alcohol-related QoL.
However, the AlQoL 9 was developed by reducing the SF-36
(French version) to the nine items most relevant to alcoholism.
The methodology for determining the relevance of the existing
items of the SF-36 was comprehensive but the adapted measure
does not include assessment of additional concepts (such as sleep
and social isolation) of particular importance for alcohol-related
QoL. CONCLUSION: There is a lack of research and assessment
of QoL in alcoholism. Individuals need to be given the opportu-
nity to determine the extent to which their QoL is impaired by
alcoholism based upon their own criteria for what constitutes
good QoL. There is a need for an alcoholism-speciﬁc QoL
measure, which focuses on the domains that are most salient to
people with such problems. Furthermore, research that includes
an assessment of the impact of alcoholism on the QoL of friends,
family and colleagues of the person abusing alcohol would also
be valuable. Only then will we be able to assess the full impact of
alcoholism (and its treatment) on QoL.
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OBJECTIVES: Caregivers’s patients with Alzheimer’s disease
(AD) experience physical and psychical stress due to the caring.
This study evaluated the beneﬁts of a Psychosocial Intervention
Program (PIP) on caregivers’ burden METHODS: A epidemio-
logical, prospective, randomized, multicenter study was con-
ducted by psychiatrists who recruited 115 primary caregivers’s of
patients with AD (DMS-IV criteria and MMSE score = 10–26)
and at least 2 impaired instrumental activities of daily living
(IADL score) by Lawton & Brody Test. Caregivers were random-
ized to receive either PIP (intervention group (IG), n = 60) or
standard care (control group (CG), n = 55). PIP consisted on
individual sessions (scheduled every 1–2 weeks during 4 months)
of teaching strategies to reduce caregiver burnout. Caregivers
stress, quality of life (QoL) and perceived health were measured
using validated scales (Zarit, SF-36, GHQ-28) at baseline, after a
4-month and a 10-month follow-up period RESULTS: The
proﬁle of patient with AD was a 77-years-old woman, with
moderate dementia (MMSEscore = 18.74) and high impairment
of daily living activities (mean IADLscore = 2.17). The caregiver
proﬁle was a 60-years-old woman, wife or adult daughter, who is
being careing for 3 years and care daily time was >12 hours,
without refund. Changes in caregiver burden (baseline
Zaritscore–ﬁnal Zaritscore) showed an improvement in the IG
(-8.09 points) and a worsening grouping the CG (+2.08 points),
with statistically signiﬁcance (p = 0.0083). The IG showed sig-
niﬁcant improvements in all the well-being perception areas mea-
sured by the SF-36scores and signiﬁcantly lower score in the
GHQ-28score (p = 0.0004). Caregivers and therapists consid-
ered PIP “useful/very useful” in a 97.7% and 88.6% respectively
at the end of PIP, and in a 93.2% and 86.3% at 6 moths after PIP
ending. CONCLUSION: Caregivers’ psychosocial training can
minimize caregiver distress and may help to develop strategies for
coping problems. PIP improves QoL and the perceived health of
caregivers of patients with AD.
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IMPROVED SLEEP IMPACT IN GENERALIZED ANXIETY
DISORDER WITH ZOLPIDEMTARTRATE EXTENDED-RELEASE
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OBJECTIVES: Insomnia is frequently associated with general-
ized anxiety disorder (GAD) and affects the patient’s day to day
life. The Sleep Impact Scale (SIS) was developed to assess the
impact of insomnia; however it has not been used in GAD.
Therefore, a study was conducted to validate the SIS and evaluate
the impact of zolpidem tartrate extended-release on insomnia in
GAD. METHODS: Validation and efﬁcacy data of the SIS were
collected alongside a randomized, placebo-controlled trial of
escitalopram + placebo or zolpidem tartrate extended-release in
adults with insomnia associated with GAD. The validation con-
sisted of evaluation of the validity and reliability, the responsive-
ness and the MID of the SIS domains to ensure the questionnaire
was acceptable in a GAD population. The efﬁcacy analysis was
performed on the ITT population, consisting of general linear
models to evaluate changes from baseline at each timepoint, with
study endpoint as the primary change score analysis. Longitudi-
nal analyses were also performed to evaluate the effects of
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